Y4877
YM 976
≥98% (HPLC)
别名:
4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H16N3OCl
化学文摘社编号:
分子量:
313.78
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41106305
MDL number:
InChI
1S/C17H16ClN3O/c1-3-13-8-9-14-15(11-6-5-7-12(18)10-11)20-17(22)21(4-2)16(14)19-13/h5-10H,3-4H2,1-2H3
SMILES string
CCN1C(=O)N=C(c2cccc(Cl)c2)c3ccc(CC)nc13
InChI key
MNHXYNNKDDXKNP-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
solid
color
yellow
mp
132.7-134.0 °C (lit.)
solubility
DMSO: ≥10 mg/mL
storage temp.
2-8°C
Biochem/physiol Actions
Phosphodiesterase type IV (PDE4) inhibitor. Anti-inflammatory activity without emesis. Related to asthma.
Phosphodiesterase type IV (PDE4) inhibitor. Exhibits anti-inflammatory activity without emesis. PDE4 inhibitors are of interest for asthma.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Massimo Nabissi et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 105, 1248-1253 (2018-07-20)
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by a progressive and irreversible airflow limitation. COPD is associated to a chronic inflammatory response with infiltration of inflammatory cells in the surface epithelium of large airways and abnormalities in
Will McDonough et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(9), 12533-12548 (2020-08-02)
Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promising therapeutic benefits, but adverse effects, in particular emesis and nausea, have curbed their clinical utility. Here, we show that PAN-selective inhibition of PDE4, but not inhibition of PDE3, causes a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持